具有改变的 E 蛋白结构域 III 表位的重组登革热 2 型病毒可被人免疫血清有效中和。
Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.
机构信息
Address correspondence to Aravinda M. de Silva,
出版信息
J Virol. 2012 Apr;86(7):4019-23. doi: 10.1128/JVI.06871-11. Epub 2012 Jan 25.
Abstract
Humans develop polyclonal, serotype-specific neutralizing antibody responses after dengue virus (DENV) infection. Many mouse antibodies that neutralize DENV bind to the lateral ridge or A strand epitopes on domain III of the viral envelope (EDIII) protein. It has been assumed that these epitopes are also the main target of human neutralizing antibodies. Using recombinant dengue serotype 2 viruses with altered EDIII epitopes, we demonstrate that EDIII epitopes are not the main target of human neutralizing antibody.
摘要
人类在感染登革病毒（DENV）后会产生多克隆、血清型特异性中和抗体反应。许多中和 DENV 的小鼠抗体结合到病毒包膜（EDIII）蛋白的 III 结构域上的侧脊或 A 链表位。人们一直认为这些表位也是人类中和抗体的主要靶标。我们使用具有改变的 EDIII 表位的重组登革热血清型 2 病毒证明，EDIII 表位不是人类中和抗体的主要靶标。
相似文献
1
Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera.具有改变的 E 蛋白结构域 III 表位的重组登革热 2 型病毒可被人免疫血清有效中和。
J Virol. 2012 Apr;86(7):4019-23. doi: 10.1128/JVI.06871-11. Epub 2012 Jan 25.
2
Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.针对登革病毒包膜结构域 III 的抗体对于血清型特异性保护或预防体内增强并不必需。
Virology. 2012 Jul 20;429(1):12-20. doi: 10.1016/j.virol.2012.03.003. Epub 2012 Apr 25.
3
Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.工程化登革病毒结构域 III 蛋白在小鼠中引发交叉中和抗体反应。
J Virol. 2018 Aug 29;92(18). doi: 10.1128/JVI.01023-18. Print 2018 Sep 15.
4
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.鉴定与人结合的登革病毒粒子上复杂表位的中和抗体。
Proc Natl Acad Sci U S A. 2012 May 8;109(19):7439-44. doi: 10.1073/pnas.1200566109. Epub 2012 Apr 12.
5
An Engineered N-Glycosylated Dengue Envelope Protein Domain III Facilitates Epitope-Directed Selection of Potently Neutralizing and Minimally Enhancing Antibodies.一种工程化 N-糖基化登革热包膜蛋白结构域 III 促进了针对强效中和和最小增强抗体的表位定向选择。
ACS Infect Dis. 2024 Aug 9;10(8):2690-2704. doi: 10.1021/acsinfecdis.4c00058. Epub 2024 Jun 29.
6
[Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus].[登革病毒包膜蛋白EⅢ区B细胞中和表位的定位]
Bing Du Xue Bao. 2015 Nov;31(6):665-73.
7
Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody.人免疫血清对登革病毒的中和作用：包膜蛋白结构域III反应性抗体的作用
Virology. 2009 Sep 15;392(1):103-13. doi: 10.1016/j.virol.2009.06.037. Epub 2009 Jul 24.
8
Paradoxical Role of Dengue Virus Envelope Protein Domain III Antibodies in Dengue Virus Infection.登革病毒包膜蛋白结构域 III 抗体在登革病毒感染中的矛盾作用。
Crit Rev Eukaryot Gene Expr. 2020;30(3):199-206. doi: 10.1615/CritRevEukaryotGeneExpr.2020028598.
9
Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.人类登革热病毒血清型 2 中和抗体靶向两个不同的四级表位。
PLoS Pathog. 2018 Feb 26;14(2):e1006934. doi: 10.1371/journal.ppat.1006934. eCollection 2018 Feb.
10
Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.寨卡病毒包膜蛋白结构域 III 作为人类中和抗体靶标的作用。
mBio. 2019 Sep 17;10(5):e01485-19. doi: 10.1128/mBio.01485-19.
引用本文的文献
1
A single residue in domain II of envelope protein of yellow fever virus is critical for neutralization sensitivity.黄热病毒包膜蛋白结构域II中的单个氨基酸残基对中和敏感性至关重要。
J Virol. 2025 Apr 15;99(4):e0177024. doi: 10.1128/jvi.01770-24. Epub 2025 Feb 28.
2
The dengue-specific immune response and antibody identification with machine learning.登革热特异性免疫反应及基于机器学习的抗体识别
NPJ Vaccines. 2024 Jan 20;9(1):16. doi: 10.1038/s41541-023-00788-7.
3
Immune-Mediated Pathogenesis in Dengue Virus Infection.登革病毒感染中的免疫介导发病机制。
Viruses. 2022 Nov 21;14(11):2575. doi: 10.3390/v14112575.
4
Innate Immune Response to Dengue Virus: Toll-like Receptors and Antiviral Response.固有免疫对登革病毒的反应： Toll 样受体与抗病毒反应。
Viruses. 2022 May 7;14(5):992. doi: 10.3390/v14050992.
5
Discovery of B-cell epitopes for development of dengue vaccines and antibody therapeutics.开发登革热疫苗和抗体治疗药物的 B 细胞表位的发现。
Med Microbiol Immunol. 2022 Feb;211(1):1-18. doi: 10.1007/s00430-021-00726-1. Epub 2022 Jan 21.
6
Subdominance in Antibody Responses: Implications for Vaccine Development.抗体反应中的次优势性：对疫苗开发的影响。
Microbiol Mol Biol Rev. 2020 Nov 25;85(1). doi: 10.1128/MMBR.00078-20.
7
Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?登革病毒的适应性免疫：合理疫苗设计的滑坡还是坚实基础？
Pathogens. 2020 Jun 15;9(6):470. doi: 10.3390/pathogens9060470.
8
Structure-Based Design of Antivirals against Envelope Glycoprotein of Dengue Virus.基于结构的登革病毒包膜糖蛋白抗病毒药物设计。
Viruses. 2020 Mar 26;12(4):367. doi: 10.3390/v12040367.
9
Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.登革病毒抗体数据库：将登革病毒血清型特异性与表位图谱进行系统关联
PLoS Negl Trop Dis. 2017 Feb 21;11(2):e0005395. doi: 10.1371/journal.pntd.0005395. eCollection 2017 Feb.
10
A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis.包膜蛋白中的单个突变可调节黄病毒的抗原性、稳定性和致病性。
PLoS Pathog. 2017 Feb 16;13(2):e1006178. doi: 10.1371/journal.ppat.1006178. eCollection 2017 Feb.
本文引用的文献
1
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.对初次感染登革病毒个体的抗体反应进行深入分析。
PLoS Negl Trop Dis. 2011 Jun;5(6):e1188. doi: 10.1371/journal.pntd.0001188. Epub 2011 Jun 21.
2
Dengue: a continuing global threat.登革热：持续的全球威胁。
Nat Rev Microbiol. 2010 Dec;8(12 Suppl):S7-16. doi: 10.1038/nrmicro2460.
3
An in-depth analysis of original antigenic sin in dengue virus infection.深入分析登革病毒感染中的原初抗原性失误。
J Virol. 2011 Jan;85(1):410-21. doi: 10.1128/JVI.01826-10. Epub 2010 Oct 27.
4
A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice.四价重组登革热病毒结构域 III 蛋白疫苗可刺激小鼠产生中和抗体和增强抗体。
Vaccine. 2010 Nov 29;28(51):8085-94. doi: 10.1016/j.vaccine.2010.10.004. Epub 2010 Oct 16.
5
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354.通过与人源单克隆抗体 CR4354 的 Fab 片段交联来中和西尼罗河病毒。
Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18950-5. doi: 10.1073/pnas.1011036107. Epub 2010 Oct 18.
6
How innate immune mechanisms contribute to antibody-enhanced viral infections.先天性免疫机制如何导致抗体增强的病毒感染。
Clin Vaccine Immunol. 2010 Dec;17(12):1829-35. doi: 10.1128/CVI.00316-10. Epub 2010 Sep 28.
7
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.人类对登革病毒的免疫反应主要由具有中和和增强活性的高度交叉反应性抗体主导。
Cell Host Microbe. 2010 Sep 16;8(3):271-83. doi: 10.1016/j.chom.2010.08.007.
8
Domain-III FG loop of the dengue virus type 2 envelope protein is important for infection of mammalian cells and Aedes aegypti mosquitoes.登革病毒 2 型包膜蛋白的结构域 III FG 环对哺乳动物细胞和埃及伊蚊的感染很重要。
Virology. 2010 Oct 25;406(2):328-35. doi: 10.1016/j.virol.2010.07.024. Epub 2010 Aug 13.
9
Genotype-specific neutralization and protection by antibodies against dengue virus type 3.针对 3 型登革热病毒的基因型特异性中和与保护作用由抗体介导。
J Virol. 2010 Oct;84(20):10630-43. doi: 10.1128/JVI.01190-10. Epub 2010 Aug 11.
10
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.抗登革病毒 2 型治疗性单克隆抗体的结构与功能分析。
J Virol. 2010 Sep;84(18):9227-39. doi: 10.1128/JVI.01087-10. Epub 2010 Jun 30.
Zotero 插件